All In Biotech

Drug Trial Radar · NCT04616586

SILtuximab in Viral ARds (SILVAR) Study

A Study Comparing the Efficacy and Safety of Standard of Care With or Without Siltuximab in Selected Hospitalized Patients With Viral Acute Respiratory Distress Syndrome (SILVAR)

Last checked: Nov 20, 2026Latest source record: Apr 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 555 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

555

Actual

Start

Nov 13, 2020

Primary completion

Apr 1, 2021

Study completion Apr 1, 2021

Sponsor

Lead sponsor
RECORDATI GROUPIndustry
Sponsor type
Industry
Collaborators
Syneos Health
First posted
Nov 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of siltuximab compared with normal saline in combination with standard of care (SOC) in selected hospitalized patients with COVID-19 previously treated with corticosteroids or another respiratory virus infection associated with acute respiratory distress syndrome (ARDS) and elevated C-reactive protein (CRP) levels.

Conditions

  • Acute Respiratory Distress Syndrome
  • Lung Diseases
  • Pneumonia
  • Respiratory Tract Infections
  • Respiratory Tract Disease

Interventions

  • SiltuximabDrug

    11 mg/kg IV administered over 1 hour

  • Normal SalineOther

    IV administered over 1 hour

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 28-day all-cause mortalityTime frame: Day 28

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Sparrow Clinical Research Institute

    Lansing, Michigan

  • Atrium Health

    Charlotte, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.